{"url_path":"/sec/imnn/8-k/2026-06-04/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/749647/0001493152-26-027201-index.html","accession_number":"0001493152-26-027201","cik":"0000749647","ticker":"IMNN","issuer_name":"Imunon, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/749647/0001493152-26-027201-index.html","primary_entity_key":"0000749647","primary_entity_name":"Imunon, Inc."},"word_count":1077,"has_tables":true,"body_markdown":"false\n--12-31\n0000749647\n\n0000749647\n\n2026-06-01\n2026-06-01\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n8-K**\n\n \n\n**CURRENT\nREPORT**\n\n \n\n**Pursuant\nto Section 13 or 15(d) of The Securities Exchange Act of 1934**\n\n \n\n**Date\nof Report (Date of earliest event reported): June 1,\n2026**\n\n \n\n**Imunon,\nInc.**\n\n**(Exact\nname of registrant as specified in its charter)**\n\n \n\n**Delaware**\n \n**001-15911**\n \n**52-1256615**\n\n**(State\nor other jurisdiction**\n\n**of\nincorporation)**\n\n \n\n**(Commission**\n\n**File\nNumber)**\n\n \n\n**(IRS\nEmployer**\n\n**Identification\nNo.)**\n\n \n\n**997\nLenox Drive****, Suite\n100****, Lawrenceville****,\nNJ**\n \n**08648-2311**\n\n**(Address\nof principal executive offices)**\n \n**(Zip\nCode)**\n\n \n\n**(609)****896-9100**\n\n**(Registrant’s\ntelephone number, including area code)**\n\n \n\n**N/A**\n\n**(Former\nname or former address, if changed since last report.)**\n\n \n\nCheck\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions (see General Instruction A.2. below):\n\n \n\n \n☐\nWritten\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n \n\n \n☐\nSoliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n \n\n \n☐\nPre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n \n\n \n☐\nPre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act\n\n \n\nTitle\nof each class\n \nTrading\nsymbol(s)\n \nName\nof each exchange on which registered\n\nCommon\nstock, par value $0.01 per share\n \nIMNN\n \nNasdaq\nCapital Market\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ☐\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\n \n\n \n\n \n\n \n\n** **\n\n**Item****1.01****Entry into\na Material Definitive Agreement.**\n\n \n\nOn\nJune 2, 2026,\nImunon, Inc. (the “**Company**”) entered into a securities purchase agreement (the “**Securities Purchase\nAgreement**”) with Streeterville Capital, LLC (the “**Investor**”), providing for the issuance and\nsale by the Company, and the purchase by the Investor, of (i) 250 shares (the “**Preferred Shares**”) of the Company’s\nSeries A Preferred Stock, par value $0.01 per share (the “**Series A Preferred Stock**”), at a price of $10,000\nper share, for aggregate proceeds of $2,500,000; (ii) a Secured Promissory Note A-1 in an original principal amount of $2,720,000 (the\n“**A-1 Note**”); and (iii) a Secured Promissory Note B in an original principal amount of $5,000,000 (the “**B\nNote**” and together with the A-1 Note, the “**Notes**”). The transactions contemplated by the Securities\nPurchase Agreement (collectively, the “**Transaction**”) closed on June 3, 2026 (the “**Closing Date**”).\n\n \n\nAt\nclosing, the Company received $10,000,000 from the Investor, $5,000,000 of which was deposited into a bank account owned by a wholly-owned\nsubsidiary of the Company as cash collateral for the Notes (the “**Cash Collateral Account**”). The obligations\nunder the Notes are secured by substantially all of the assets of the Company, other than its intellectual property assets, and are guaranteed\nby certain of the Company’s subsidiaries. The Company intends to utilize the other $5,000,000 of proceeds from the closing of the\nTransaction, along with any proceeds later released from the Cash Collateral Account, for general corporate purposes, including research\nand development activities, capital expenditures and working capital. The Company agreed to pay the placement agents for the financing\na fee of 7.0% of the gross proceeds received by the Company in connection with the Transaction.\n\n \n\nIf\nthe aggregate outstanding balance of the A-1 Note or the aggregate number of outstanding Preferred Shares is reduced by $2,000,000 (or,\nif less than $2,000,000, the entire remaining outstanding balance of the A-1 Note), the Company will have the right to exchange up to\n$1,000,000, plus interest (or, if less than $1,000,000, the entire remaining amount of the B Note, or such other amount as the parties\nmutually agree), of the B Note for a new secured note in the same form and having the same terms as the A-1 Note (each, a “**Note\nExchange**”). Upon the completion of each Note Exchange, an amount of cash equal to the amount of the B Note exchanged in\nsuch Note Exchange will be released from the Cash Collateral Account to the Company.\n\n \n\nThe\nA-1 Note will bear interest at 8% per annum and will mature 18 months following the Closing Date. The B Note will bear interest at 5%\nper annum and will mature 18 months following the Closing Date. The Notes can be prepaid by the Company in whole or in part at any time,\nsubject to a 10% prepayment premium on any principal amounts prepaid.\n\n \n\nBeginning\nsix months after the Closing Date, the Investor may redeem up to $250,000 of the principal amount of the A-1 Note each calendar month.\nIn addition, on any trading day when the Company’s common stock trades at a price that is at least 15% greater than the “Minimum\nPrice” as defined under Nasdaq Stock Market LLC Rule 5635(d), the Investor may redeem an additional principal amount of the Notes\nequal to 5% of the trading volume of the Company’s common stock on such trading day.\n\n \n\nThe\nCompany will be subject to customary covenants while the Notes remain outstanding. The Notes also contain customary events of default,\nthe occurrence of which would permit the Investor to accelerate the obligations under the Notes and exercise remedies against any collateral\n(including amounts on deposit in the Cash Collateral Account) or guarantees in respect of the Notes. In addition, following the occurrence\nof an event of default, the interest rate of each Note would increase to the lesser of 15% per year or the maximum rate permitted by\napplicable law.\n\n \n\nThe\nforegoing descriptions of the Securities Purchase Agreement, A-1 Note and B Note do not purport to be complete and are qualified in their\nentirety by reference to the full text of such documents, copies of which are filed as Exhibits 10.1, 10.2 and 10.3, respectively, to\nthis Current Report on Form 8-K and are incorporated herein by reference. Each of the Securities Purchase Agreement, A-1 Note and B Note\ncontains representations, warranties and other provisions that were made only for purposes of the applicable agreement and as of specific\ndates, are solely for the benefit of the parties thereto, and may be subject to limitations agreed upon by such parties."}